Pharmacy Focus

Pharmacy Times

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy. Winner of the 2021 Digital Health Media/Publications Audio Merit Award. 

  1. 1d ago

    Managing Postpartum Psychosis Through Lithium-Based Treatment, Screening, and Team-Based Care

    In this episode of Psychiatric Pharmacy Pulse, host Megan Maroney, PharmD, BCPP, FAAPP, and guest Mei T. Liu, PharmD, BCPP, both of whom are clinical associate professors at the Ernest Mario School of Pharmacy, look at postpartum psychosis. It is somewhat rare, occurring in about 1 to 2 per 1000 births, but it is an obstetric and psychiatric emergency that should be treated in the inpatient setting. Symptoms usually begin 3 to 10 days after delivery and can include hallucinations, delusions, rapid mood swings, and thoughts of harming oneself or the infant. Bipolar disorder is among the strongest predictors. Up to almost 1 in 5 deliveries in women with bipolar disorder result in postpartum psychosis, and about half of patients go on to be diagnosed with bipolar disorder or another psychiatric condition. Family history, previous episodes, and sleep disturbances also raise risk, although about one-third of patients have no psychiatric history. There is no universal screening recommendation for postpartum psychosis. Still, the American College of Obstetricians and Gynecologists (ACOG) recommends that all patients receiving prenatal and postpartum care be screened for bipolar disorder with a validated tool before treatment for depression or anxiety starts. The hosts point to the brief, scripted Composite International Diagnostic Interview bipolar screen and to ACOG’s standardized suicide risk screener as practical tools for clinicians outside psychiatry. They also explain how to tell common intrusive, anxiety-driven thoughts apart from high-risk thoughts of harming the infant. In the high-risk case, the thoughts feel comforting or justified to the patient and come with a lack of insight.On treatment, Maroney and Liu describe a staged approach. A benzodiazepine comes first, an antipsychotic is added if needed, and lithium follows. Most patients respond to lithium, which ACOG also considers the gold standard for preventing future episodes. They suggest about 9 months of maintenance therapy followed by an individualized reassessment. They also discuss breastfeeding: lithium requires infant monitoring and pediatrician involvement, lamotrigine is a concern because of high passage into breast milk, and electroconvulsive therapy is an option. They advise avoiding antidepressants when possible because of the risk of switching into mania. The episode closes with resources, including the National Maternal Mental Health Hotline (1-833-TLC-MAMA) and the peer support group Action on Postpartum Psychosis. REFERENCES Newmark RL, Bogen DL, Wisner KL, Isaac M, Ciolino JD, Clark CT. Risk-Benefit assessment of infant exposure to lithium through breast milk: a systematic review of the literature. International Review of Psychiatry. 2019;31(3):295–304. doi:10.1080/09540261.2019.1586657 Bergink V, Akbarian S, Byatt N, et al. Postpartum Psychosis and Bipolar Disorder: Review of Neurobiology and Expert Consensus Statement on Classification. Biol Psychiatry. 2026;99(9):740-747. doi:10.1016/j.biopsych.2025.10.016 Bergink V, Burgerhout KM, Koorengevel KM, et al. Treatment of psychosis and mania in the postpartum period. American Journal of Psychiatry. 2015;172(2):115-123. doi:10.1176/appi.ajp.2014.13121652 ACOG Committee on Clinical Practice Guidelines-Obstetrics. Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 4. Obstet Gynecol. 2023;141(6):1232-1261. doi:10.1097/AOG.0000000000005200 ACOG Committee on Clinical Practice Guidelines-Obstetrics. Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 5. Obstet Gynecol. 2023;141(6):1262-1288. doi:10.1097/AOG.0000000000005202 Wisner KL, Murphy C, Thomas MM. Prioritizing Maternal Mental Health in Addressing Morbidity and Mortality. JAMA Psychiatry. 2024;81(5):521-526. doi:10.1001/jamapsychiatry.2023.5648 Almeida M. The Maternal Mental Health Crisis-A Dangerous Blind Spot in US Medicine. JAMA. 2026;336(15):1303-1304. doi:10.1001/jama.2026.20213 Friedman SH, Reed E, Ross NE. Postpartum Psychosis. Curr Psychiatry Rep. 2023;25(2):65-72. doi:10.1007/s11920-022-01406-4 To provide feedback or suggest topics of discussion for Psychiatric Pharmacy Pulse, please reach out to Gillian McGovern, Editor (gmcgovern@pharmacytimes.com).

    Managing Postpartum Psychosis Through Lithium-Based Treatment, Screening, and Team-Based Care
  2. Nov 12

    Program Directors Make the Case for PGY2 Training to Build the Neurology Pharmacy Pipeline

    In this episode of Mind the Meds, host Erica Marini, PharmD, MS, BCPS, speaks with Kat Chester, PharmD, BCCCP, BCGP, FNCS, a PGY2 neurology residency program director at Grady Memorial Hospital in Atlanta, and Michael Armahizer, PharmD, BCCCP, a clinical pharmacy specialist in neurocritical care at the University of Maryland Medical Center. Marini notes that the American Society of Health-System Pharmacists directory lists roughly 6 formal neurology training positions, compared with 55 PGY2 programs in cardiology and 199 in critical care. Both guests came to neurology without dedicated training and describe how their programs grew out of expanding neurology services, institutional support, and a market survey showing demand for neurology-trained pharmacists.Both Chester and Armahizer make the case that a PGY2 offers depth that a short rotation or on-the-job learning cannot. Residents get repeated exposure to complex cases such as refractory status epilepticus and see neurologic care across inpatient and outpatient settings. Chester points to the volume of practice-changing literature and to the share of new FDA approvals related to neurology, which she puts at about 1 in 5 to 1 in 7. Chester and Armahizer note that they expect the greatest growth to be in ambulatory care, driven by antiamyloid therapies, multiple sclerosis disease-modifying therapies, neonatal Fc receptors and complement inhibitors for myasthenia gravis, and new migraine treatments. They name proving return on investment, low awareness of what pharmacists contribute, and a limited workforce as the main barriers.For PGY1 residents weighing the specialty, Chester rejects 3 common misconceptions: that neurology is too niche, too difficult, or short on career opportunities. They both recommend taking a neurology or neurology-adjacent rotation and talking with practicing neurology pharmacists. Midcareer pharmacists can build expertise through protocol work, mentorship programs, organizations such as Certified Pediatric Nurse Practitioner, the Neurocritical Care Society, and the American Academy of Neurology, and by teaching. Residency graduates are seen as neurology’s strongest advocates, because they start new programs and help train medical residents who later push for pharmacists on their own teams.

    Program Directors Make the Case for PGY2 Training to Build the Neurology Pharmacy Pipeline
  3. Nov 5

    October Neurology News: Huntington Disease Gene Therapy, Remibrutinib in MS, and AI Medical Advice

    In this update episode of Mind the Meds, host Erica Marini, PharmD, MS, BCPS, opens with regulatory news. The FDA accepted uniQure’s application for AMT-130, a gene therapy for Huntington disease, under priority review. An advisory committee meeting is tentatively planned, and a decision is possible in May 2027. AV-1959R (Nuravax, Inc), an investigational amyloid-β vaccine, received fast track designation for preventing Alzheimer disease in cognitively unimpaired individuals with biomarker evidence of amyloid pathology. FDA decisions are expected in November on asundexian (Bayer HealthCare), an oral factor XIa inhibitor for secondary stroke prevention, and cemdisiran (Regeneron), a C5-targeting small interfering RNA for generalized myasthenia gravis. Marini also notes the $5.6 billion acquisition of Option Care, a major infusion provider. The deal is expected to close in early 2027 and could affect outpatient neurology pharmacy teams.On the clinical side, Bristol Myers Squibb reported the death of a patient with multiple sclerosis after its chimeric antigen receptor (CAR) T-cell trials were halted. In the phase 3 REMODEL-1 (NCT05147220) and REMODEL-2 (NCT05156281) trials, the Bruton tyrosine kinase inhibitor remibrutinib (Rhapsido; Novartis) reduced annualized relapse rates by approximately 35% and 31.2% vs teriflunomide (Aubagio; Genzyme Corp), with no liver safety concerns. However, its effect on 3-month confirmed disability progression was not statistically significant. Other studies found: a marginal, likely not clinically relevant, difference in relapse rates between ofatumumab (Kesimpta; Novartis) and ocrelizumab (Ocrevus; Genentech); a higher risk of inflammatory bowel disease with rituximab (Rituxan; Genentech, Biogen; number needed to harm, 131 at 5 years); a negative phase 2 HIMALAYA trial (NCT05237284) of SAR443820 in amyotrophic lateral sclerosis; a higher risk of spontaneous abortion with early pregnancy exposure to anti-CGRP monoclonal antibodies than with propranolol; and positive topline phase 3 results for solengepras (Cerevance), which reduced daily off time in Parkinson disease. Marini closes with a New York Times report on a woman with epilepsy who died after following ChatGPT’s plan to stop her antiseizure medication. The chatbot also undermined her trust in her physician and dismissed her symptoms as she tapered off. That model has since been taken offline. Marini says she hopes for regulation and urges pharmacists to make themselves available so patients have a real person to turn to with medication questions.

    October Neurology News: Huntington Disease Gene Therapy, Remibrutinib in MS, and AI Medical Advice
  4. Oct 15

    What Cannabis Rescheduling Means for Pharmacists, Patients, and Psychiatric Care

    In this episode of Psychiatric Pharmacy Pulse, host Megan Maroney, PharmD, BCPP, FAAPP, talks with Mary Bridgeman, PharmD, a pharmacist and clinical professor at the Ernest Mario School of Pharmacy at Rutgers, about the federal effort to move cannabis from Schedule I to Schedule III of the Controlled Substances Act. Bridgeman explains that the federal order covers FDA-approved cannabis products and those dispensed under state medical marijuana licenses. Adult-use cannabis, bulk plant material, and synthetically derived THC remain in Schedule I while the broader rescheduling goes through the hearing process. Because state rules vary so widely, Bridgeman says pharmacists in any practice setting should expect questions from patients and colleagues about cannabis use, its legal status, and its potential benefits and harms.Maroney goes over the main CYP interactions for CBD and THC and notes that smoking cannabis induces CYP1A2. Bridgeman adds that pharmacodynamic effects, such as more sedation and anticholinergic effects, matter too. Drawing on Canada’s lower-risk cannabis guidelines, Maroney outlines harm reduction counseling: avoid driving for 6 to 8 hours after inhaling and longer after oral use, delay use until after adolescence, choose lower-potency or higher CBD-to-THC products, and avoid smoking. Bridgeman cites the 2025 SAMHSA National Survey on Drug Use and Health. It estimates that 21 million Americans use cannabis daily or near daily, more than the number who drink alcohol daily, and that 19.3 million had cannabis use disorder in the past year.Maroney also covers higher-risk groups. These include people with severe mental illness, among whom cannabis use rose after recreational legalization, and people who are pregnant or trying to conceive. She cites Danish data showing that 47.4% of patients with cannabis-induced psychosis were later diagnosed with schizophrenia or bipolar disorder. On the positive side, both guests expect rescheduling to lower research barriers and improve access for patients who may benefit, such as those with chronic pain, chemotherapy-induced nausea and vomiting, or multiple sclerosis spasticity. Bridgeman’s main advice is for pharmacists to keep up with the changing federal rules and the evidence. REFERENCES US Drug Enforcement Administration. Marijuana Rescheduling Regulatory Actions. Published 2026. Accessed October 14, 2026. https://www.dea.gov/marijuana-rescheduling-regulatory-actions Public Health Agency of Canada. Canada’s Lower-Risk Cannabis Use Guidelines. Published May 10, 2019. Updated January 22, 2020. Accessed October 14, 2026. https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/resources/lower-risk-cannabis-use-guidelines.html Substance Abuse and Mental Health Services Administration. 2025 National Survey on Drug Use and Health (NSDUH) Releases. Updated August 17, 2026. Accessed October 14, 2026. https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health/national-releases/2025 VERTANICAL. FDA grants Breakthrough Therapy Designation to VERTANICAL’s VER-01, a first-in-class non-opioid investigational treatment for chronic low back pain. PR Newswire. May 18, 2026. Accessed October 14, 2026. https://www.prnewswire.com/news-releases/fda-grants-breakthrough-therapy-designation-to-vertanicals-ver-01-a-first-in-class-non-opioid-investigational-treatment-for-chronic-low-back-pain-302774621.html Hyatt AS, Flores MW, Johnson J, et al. Cannabis use among individuals with psychosis after state-level commercial cannabis legalization. JAMA Psychiatry. 2026;83(1):74-77. doi:10.1001/jamapsychiatry.2026 Kansagara D, Terry GE, Ayers CK, D’Souza DC. Cannabis and mental health: a review. JAMA Intern Med. 2026;186(5):618-628. doi:10.1001/jamainternmed.2026 Sheth S, Maroney M, Bridgeman MB. Cannabis at a crossroads: pharmacist care considerations in the context of a changing cannabis regulatory landscape. J Am Pharm Assoc (2003). 2025;65(3):102361. doi:10.1016/j.japh.2025.102361 Young-Wolff KC, Cortez CA, Alexeeff SE, et al. Adolescent cannabis use and risk of psychotic, bipolar, depressive, and anxiety disorders. JAMA Health Forum. 2026;7(2):e256839. doi:10.1001/jamahealthforum.2026.6839 Starzer MSK, Nordentoft M, Hjorthøj C. Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. Am J Psychiatry. 2018;175(4):343-350. doi:10.1176/appi.ajp.2017.17050535 Daniel NM, Maroney M. Rates of conversion from substance-associated psychotic disorder to bipolar or schizophrenia spectrum disorder in a community-based teaching hospital. J Clin Psychopharmacol. 2020;40(2):212-213. doi:10.1097/JCP.0000000000001187 To provide feedback or suggest topics of discussion for Psychiatric Pharmacy Pulse, please reach out to Gillian McGovern, Editor (gmcgovern@pharmacytimes.com).

    What Cannabis Rescheduling Means for Pharmacists, Patients, and Psychiatric Care
  5. Oct 8

    Inside the New Consensus Recommendations for Acute Stroke Care

    In this episode of Mind the Meds, host Erica Marini, PharmD, opens with the month's neurology pharmacy news: Novartis and Bristol Myers Squibb paused CAR T-cell trials in autoimmune diseases, including myasthenia gravis and multiple sclerosis, after safety concerns. FDA approvals included tavapadon (Juvmo; AbbVie), a selective D1/D5 dopamine agonist for Parkinson disease; apitegromab (Isembyld; Scholar Rock), an add-on myostatin inhibitor for spinal muscular atrophy; and levacetylleucine (Aqneursa; IntraBio Inc) for ataxia-telangiectasia.  FDA also granted priority review to satralizumab (Genentech) for relapsing myelin oligodendrocyte glycoprotein antibody–associated disease. Currently, it is approved for anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder under the brand name Enspryng. Marini closes the segment with positive results for ulefnersen (Ionis Pharmaceuticals, Otsuka Pharmaceutical) in FUS-ALS in the phase 3 FUSION trial (NCT04768972) and for atogepant (Qulipta; AbbVie) in menstrual migraine prevention. Marini is then joined by Caitlin S. Brown, PharmD, MPH, BCCCP, FCCM, FCCP, associate professor of pharmacy and emergency medicine at Mayo Clinic; and Brian Gilbert PharmD, MBA, FCCM, FNCS, FCCP, FASHP, FKCHP, a former emergency medicine clinical pharmacy specialist. Both are authors of the consensus recommendations on integrating clinical pharmacists into the acute stroke care team, published in the Journal of the American College of Clinical Pharmacy.1 The project grew out of the authors’ systematic reviews on pharmacist involvement in ischemic and hemorrhagic stroke. Their panel brought together emergency medicine and neurocritical care pharmacists from academic and community settings, emergency physicians, a neurologist, a librarian, and a statistician. The recommendations were endorsed by the American College of Clinical Pharmacy, the Neurocritical Care Society, the Society for Academic Emergency Medicine, and the Society of Critical Care Medicine, and affirmed by the American Academy of Neurology. Gilbert notes that this multidisciplinary support gives pharmacy leaders evidence they can bring to administrators when making the case for new full-time equivalent positions. Brown and Gilbert walk through the evidence behind both recommendations. Across 10 studies in acute ischemic stroke, pharmacist involvement cut time to thrombolytic administration by about 15 minutes and helped teams meet 45- and 60-minute door-to-needle goals more often. In 6 hemorrhagic stroke studies, pharmacist involvement shortened time to reversal agent administration. The evidence is mostly low-quality retrospective data, and there are no functional outcomes data yet, so the authors relied on time-based surrogate end points. They explain that their hope is future research will capture the full range of pharmacist interventions, that telestroke services will bring pharmacists in to support rural hospitals, and that later American Heart Association (AHA) guidelines will specifically name pharmacists as members of the stroke team. The episode ends with a look back at the January 2026 AHA ischemic stroke guidelines. Most centers had already switched to tenecteplase (TNKase; Genentech), and the guests say the bigger questions now are dosing strategy and whether to keep alteplase (Activase; Genentech) on formulary. They also discuss the extended thrombolysis window of up to 9 hours for patients with favorable imaging, which they expect to spread slowly outside academic centers. Other topics include the new guidance on alteplase for pediatric stroke, which both guests have given only once, and the caution against lowering blood pressure too far after reperfusion. REFERENCEGilbert BW, Brown CS, Acquisto NM, et al. Consensus recommendations for clinical pharmacist integration into the acute stroke care team: Endorsed by the American College of Clinical Pharmacy, Neurocritical Care Society, Society for Academic Emergency Medicine, and Society of Critical Care Medicine, and affirmed by the American Academy of Neurology. J Am Coll Clin Pharm. 2026;9(7):e70246. doi:10.1002/jac5.70246

    Inside the New Consensus Recommendations for Acute Stroke Care
  6. Sep 17

    Centanafadine May Offer Second-Line Option for Patients With ADHD If Stimulants Fail

    In this episode of Psychiatric Pharmacy Pulse, host Megan Maroney, PharmD, BCPP, FAAPP, speaks with Danielle Stutzman, PharmD, BCPP, clinical assistant professor at the University of Colorado Skaggs School of Pharmacy and assistant adjunct professor at the Child and Adolescent Mental Health Division of the Department of Psychiatry at the University of Colorado School of Medicine, and member of the American Association of Psychiatric Pharmacists Board of Directors, about where centanafadine (Simtriyo; Otsuka Pharmaceutical) fits into attention-deficit/hyperactivity disorder (ADHD) pharmacotherapy. Centanafadine received FDA approval in July 2026 as a norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI) for ADHD in both pediatric and adult patients, with DEA scheduling still pending. Maroney and Stutzman note its mechanism is not entirely novel, drawing comparisons to tricyclic antidepressants, atomoxetine (Eli Lilly), and viloxazine (Qelbree; Supernus Pharmaceuticals, Inc).  A pooled meta-analysis of 4 phase 3 trials plus a phase 2b crossover study found a Hedges’ g effect size of about 0.37 for overall symptom severity versus placebo, a modest result that falls short of typical stimulant effect sizes of 0.8 to 1.0, though executive functioning outcomes on caregiver-rated scales appeared more promising. Safety data showed a nonsignificant increase in adverse effects (AEs) overall (pooled risk ratio, 1.29), with appetite suppression, nausea, and rash among the most common issues. Rash was the leading cause of study discontinuation in the youngest age group. Indirect comparisons suggested centanafadine may carry a lower risk of insomnia than methylphenidate and fewer AEs than atomoxetine and viloxazine, though lisdexamfetamine (Vyvanse; Takeda Pharmaceuticals) remained more effective. A boxed warning for suicidal ideation applies, which is consistent with other ADHD medications. Practical advantages discussed include a lack of reliance on cytochrome P450 metabolism, lower drug interaction risk than atomoxetine or viloxazine, and capsules that can be opened and sprinkled on applesauce, yogurt, or orange juice. Centanafadine did increase caffeine exposure roughly 2-fold, warranting patient counseling. Both Maroney and Stutzman positioned the drug as a potential second-line option for patients who are not candidates for stimulants or who have not tolerated or responded to first-line therapies.To provide feedback or suggest topics of discussion for Psychiatric Pharmacy Pulse, please reach out to Gillian McGovern, Editor (gmcgovern@pharmacytimes.com).REFERENCES1. Mattingly GW, Turkoglu O, Chang D, Ward C, Skubiak T, Zhang Z, Cutler AJ. 52-week open-label safety and tolerability study of centanafadine sustained release in adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2025;45(5):454-462. doi:10.1097/JCP.00000000000020202. Otsuka Pharmaceutical Development & Commercialization, Inc; Otsuka Pharmaceutical Co, Ltd. Otsuka receives FDA approval for first-in-class SIMTRIYO (centanafadine) for the treatment of attention-deficit/hyperactivity disorder. Otsuka US. July 24, 2026. Accessed September 16, 2026. https://www.otsuka-us.com/otsuka-shares-fda-review-update-for-centanafadine3. Adler LA, Adams J, Madera-McDonough J, et al. Efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder: results of 2 phase 3, randomized, double-blind, multicenter, placebo-controlled trials. J Clin Psychopharmacol. 2022;42(5):429-439. doi:10.1097/JCP.00000000000015754. Muneer MA, Naveed M, Amjad M, et al. Efficacy and safety of centanafadine in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis of randomized controlled trials. Psychopharmacol Bull. 2026;56(3):47-65. https://pubmed.ncbi.nlm.nih.gov/42267239/5. Schein J, Cloutier M, Gauthier-Loiselle M, et al. Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: a matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release. J Manag Care Spec Pharm. 2024;30(6):528-540. doi:10.18553/jmcp.2024.30.6.5286. Stein MA. Editorial: centanafadine for adolescents with attention-deficit/hyperactivity disorder: is a broader mechanism of action better? J Am Acad Child Adolesc Psychiatry. 2026;65(6):764-765. doi:10.1016/j.jaac.2025.10.0207. Ward CL, Childress AC, Jin N, et al. Centanafadine for attention-deficit/hyperactivity disorder in adolescents: a randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2026;65(6):805-817. doi:10.1016/j.jaac.2025.06.023

    Centanafadine May Offer Second-Line Option for Patients With ADHD If Stimulants Fail

Ratings & Reviews

4.7
out of 5
11 Ratings

About

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy. Winner of the 2021 Digital Health Media/Publications Audio Merit Award. 

You Might Also Like